Manish Gera
Nephrology · Terre Haute, INNPI 1497729818
Payments from drug & device makers
Across 558 payments — averaging $202.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$40K
- Calliditas Therapeutics US Inc.$31K
- Vifor Pharma, Inc.$16K
- Mallinckrodt Enterprises LLC$13K
- Mallinckrodt Hospital Products Inc.$5K
- Bayer$2K
- plus $6K from 28 others
What the payments were for
- Consulting fees$5,8885%
- Speaking & faculty fees$81,70072%
- Travel & lodging$11,62210%
- Food & beverage$12,93811%
- Education$6801%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 109 | $40,374 |
| Calliditas Therapeutics US Inc. | 42 | $30,600 |
| Vifor Pharma, Inc. | 57 | $15,942 |
| Mallinckrodt Enterprises LLC | 16 | $12,927 |
| Mallinckrodt Hospital Products Inc. | 20 | $4,945 |
| Bayer | 31 | $2,242 |
| Fresenius USA Marketing, Inc. | 48 | $966 |
| Amgen(2 entities) | 54 | $837 |
| Novartis | 27 | $541 |
| Astellas Pharma US Inc | 7 | $408 |
| Novo Nordisk | 16 | $343 |
| Travere Therapeutics, Inc. | 12 | $335 |
| Otsuka America Pharmaceutical, Inc. | 11 | $296 |
| OPKO Pharmaceuticals, LLC | 20 | $281 |
| Sumitomo Pharma America, Inc. | 12 | $267 |
| Aurinia Pharma U.S., Inc. | 10 | $200 |
| Boehringer Ingelheim | 9 | $198 |
| Ardelyx, Inc. | 9 | $188 |
| GSK | 6 | $104 |
| Lilly USA, LLC | 6 | $103 |
| Akebia Therapeutics Inc | 4 | $85 |
| Lundbeck LLC | 5 | $82 |
| Urovant Sciences Inc | 4 | $80 |
| Daiichi Sankyo Inc. | 4 | $73 |
| Shire North American Group Inc | 4 | $68 |
| ANI Pharmaceuticals, Inc. | 2 | $58 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $54 |
| Baxter Healthcare | 1 | $48 |
| Johnson & Johnson | 3 | $46 |
| Shield Therapeutics Inc | 2 | $46 |
| Ultragenyx Pharmaceutical Inc. | 2 | $34 |
| Apellis Pharmaceuticals, Inc. | 1 | $27 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$112,828 in reported general payments places this provider in the 90th percentile of 238 nephrology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JynarqueTolvaptan | 13 | $256,767 |
| Tolvaptan | 39 | $204,692 |
| FarxigaDapagliflozin Propanediol | 296 | $191,200 |
| LokelmaSodium Zirconium Cyclosilicate | 150 | $135,048 |
| VelphoroSucroferric Oxyhydroxide | 38 | $132,542 |
| JardianceEmpagliflozin | 121 | $88,623 |
| XphozahTenapanor Hcl | 30 | $84,361 |
| GemtesaVibegron | 70 | $55,074 |
| MyrbetriqMirabegron | 90 | $51,685 |
| VeltassaPatiromer Calcium Sorbitex | 43 | $34,445 |
| KerendiaFinerenone | 36 | $33,497 |
| AuryxiaFerric Citrate | 23 | $29,007 |
| Potassium Chloride | 671 | $20,674 |
| Midodrine Hcl | 171 | $20,102 |
| Sevelamer Carbonate | 98 | $16,152 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $40,374 | $326,248446 claims |
| Otsuka America Pharmaceutical, Inc.Jynarque | $296 | $256,76713 claims |
| Fresenius USA Marketing, Inc.Velphoro | $966 | $132,54238 claims |
| Boehringer IngelheimJardiance | $198 | $88,623121 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $267 | $55,07470 claims |
| Astellas Pharma US IncMyrbetriq | $408 | $51,68590 claims |
| BayerKerendia | $2,242 | $33,49736 claims |
| Akebia Therapeutics IncAuryxia | $85 | $29,00723 claims |
| NovartisEntresto | $541 | $9,58312 claims |
| PfizerEliquis | $13 | $7,35516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 238 nephrology providers in Indiana.
Other nephrology in Terre Haute
- Gaurav VermaTerre Haute$149K
- Raj JeevanTerre Haute$5K
- Andrew OshaughnessyFort Wayne$1.2M
- Rajiv AgarwalIndianapolis$1.2M
- Garima GuptaFort Wayne$666K
- Jay WishIndianapolis$502K
- Bruce MolitorisIndianapolis$471K
- Kenneth ChoiMerrillville$392K
- Arjun SinhaIndianapolis$315K
- Sharon MoeIndianapolis$298K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.